Inmune Bio (INMB) Change in Receivables (2023 - 2026)
Inmune Bio (INMB) posted Change in Receivables of -$3.8 million for Q1 2026, down 247.48% sequentially from $2.6 million in Q4 2025, and down 3830.39% YoY from $102000.0 in Q1 2025.
Inmune Bio (INMB) Change in Receivables (2023 - 2026) Analysis & Trends
Inmune Bio has reported Change in Receivables for 4 years, with the latest figure at -$3.8 million in Q1 2026.
- Quarterly Change in Receivables fell 3830.39% year-over-year to -$3.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$804000.0 (up 5.41% YoY) and the FY2025 annual result came in at $3.1 million, up 528.59% from the prior year.
- Change in Receivables fell to -$3.8 million in Q1 2026 per INMB's latest filing, from $2.6 million in the prior quarter.
- Over five years, Change in Receivables peaked at $2.6 million in Q4 2025 and troughed at -$3.8 million in Q1 2026.
- A 4-year average of -$132272.7 and a median of $102000.0 in 2025 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2025 and 2026: Change in Receivables surged 3483.33% in 2025, then sank 3830.39% in 2026.
- Over 4 years, Change in Receivables stood at -$182000.0 in 2023, then soared by 139.56% to $72000.0 in 2024, then soared by 3483.33% to $2.6 million in 2025, then tumbled by 247.48% to -$3.8 million in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered -$3.8 million, $2.6 million, and $99000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inmune Bio | 61.59 Mn | 43.18 Mn | - | 3.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.93 Mn |
| Jun 30, 2026 | 3.93 Mn |
| Mar 31, 2026 | -3.81 Mn |
| Mar 31, 2026 | -3.81 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Dec 31, 2025 | 2.58 Mn |
| Sep 30, 2025 | 99,000.00 |
| Sep 30, 2025 | 99,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Jun 30, 2025 | 322,000.00 |
| Mar 31, 2025 | 102,000.00 |
| Mar 31, 2025 | 102,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Dec 31, 2024 | 72,000.00 |
| Sep 30, 2024 | -2.03 Mn |
| Sep 30, 2024 | -2.03 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 228,000.00 |
| Mar 31, 2024 | 228,000.00 |